Spectroscopic Quality Monitoring of Cefepime

Cefepime for Injection, a broad-spectrum fourth-generation cephalosporin, is indicated for treating serious infections including pneumonia, febrile neutropenia, urinary tract infections, and intra-abdominal infections. This study utilizes non-invasive Fourier transform near-infrared (FTNIR) spectrometry to evaluate the manufacturing quality and consistency of cefepime drug product. The investigation revealed significant intralot variability within a single manufacturing lot (5056KFPDL1), Principal Component Analysis (PCA) of this lot showed that the first two principal components (PCs) accounted for 99.72% of total spectral variation, and subcluster analysis identified two distinct groups of vials with statistical significance (p=0.02). Furthermore, interlot variability was documented across a spectral library of 222 vials from 17 different manufacturing lots. Significant spectroscopic variations were observed between lots. PCA of the interlot library indicated that the first three PCs collectively captured 87.83% of total variation, revealing the existence of multiple distinct clusters or "families" of vials rather than a uniform population. While these results do not definitively prove impurities, they strongly suggest the manufacturing process may be operating outside of a state of process control, warranting further investigation to ensure pharmaceutical supply chain integrity.